BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dizal Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Dizal Pharmaceuticals's drugs run
 \, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07070440-2251@assetmemo.bio
DTSTAMP:20261121T010129Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:DZD6008: Phase 1/2 readout est. (NCT07070440)
DESCRIPTION:DZD6008\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: DZD60
 08 Combination Therapy in Patients With Locally Advanced or Metastatic NSC
 LC With EGFR Mutation (TIAN-SHAN7)\nEstimated primary completion: June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/dzd6008#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07070440
URL:https://assetmemo.bio/drug/dzd6008#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07079475-2163@assetmemo.bio
DTSTAMP:20261121T010129Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Zegfrovy (Sunvozertinib): Phase 1/2 readout est. (NCT07079475)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase 1/2\, Non-Small Cell Lung Canc
 er.\nStudy: Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertin
 ib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)\nE
 stimated primary completion: June 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sunvozertinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07079475
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07182682-2163@assetmemo.bio
DTSTAMP:20261121T010129Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Zegfrovy (Sunvozertinib): Phase 3 readout est. (NCT07182682)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase 3\, Non-Small Cell Lung Cancer
 .\nStudy: A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Ther
 apy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR
  Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery\nEsti
 mated primary completion: September 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/sunvozertinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07182682
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
